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Systems approach reveals photosensitivity and
PER2 level as determinants of clock-modulator
efficacy
Dae Wook Kim1 , Cheng Chang2,* , Xian Chen3, Angela C Doran4, Francois Gaudreault5,
Travis Wager6, George J DeMarco7 & Jae Kyoung Kim1,**
Abstract
In mammals, the master circadian clock synchronizes daily
rhythms of physiology and behavior with the day–night cycle.
Failure of synchrony, which increases the risk for numerous
chronic diseases, can be treated by phase adjustment of the
circadian clock pharmacologically, for example, with melatonin,
or a CK1d/e inhibitor. Here, using in silico experiments with a
systems pharmacology model describing molecular interactions,
and pharmacokinetic and behavioral experiments in cynomol-
gus monkeys, we find that the circadian phase delay caused
by CK1d/e inhibition is more strongly attenuated by light in
diurnal monkeys and humans than in nocturnal mice, which
are common preclinical models. Furthermore, the effect of
CK1d/e inhibition strongly depends on endogenous PER2
protein levels, which differs depending on both the molecular
cause of the circadian disruption and the patient’s lighting
environment. To circumvent such large interindividual varia-
tions, we developed an adaptive chronotherapeutics to identify
precise dosing regimens that could restore normal circadian
phase under different conditions. Our results reveal the impor-
tance of photosensitivity in the clinical efficacy of clock-modu-
lating drugs, and enable precision medicine for circadian
disruption.
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Introduction
Circadian (~24 h) rhythms of diverse behavioral and physiological
processes such as sleep and hormone secretion are coordinated by
an endogenous timer, the circadian clock (Dibner et al, 2010). The
key oscillatory molecular mechanism of the mammalian circadian
clock centers around the PER1/2 proteins that mediate an autoregu-
latory negative feedback loop of their own transcription (Ukai &
Ueda, 2010; Aryal et al, 2017; Takahashi, 2017). This generates
circadian expression of PER1/2 at both the mRNA and protein
levels. The period and phase of PER1/2 oscillations are further regu-
lated by post-translational control of their stability and subcellular
localization via CK1d/e phosphorylation (Vanselow et al, 2006;
Gallego & Virshup, 2007; Kaasik et al, 2013; Qin et al, 2015; Zhou
et al, 2015; Shinohara et al, 2017; Narasimamurthy et al, 2018; Ode
& Ueda, 2018). Thus, CK1d/e is being considered as an effective
pharmacologic target for the manipulation of circadian rhythms
(Badura et al, 2007; Sprouse et al, 2009, 2010; Meng et al, 2010;
Kim et al, 2013; Pilorz et al, 2014). The phase of circadian rhythms
can also be adjusted by Per1/2 gene transcription induced by exter-
nal light, which is transmitted from the retina to the hypothalamic
suprachiasmatic nucleus (SCN) via the retinohypothalamic tract
(Hattar et al, 2002; Gallego & Virshup, 2007). This leads to the
entrainment of the endogenous circadian system to the external
day–night cycle (Wright et al, 2013).
The failure of synchrony between the clock and external cycles
can occur due to dysfunction of the circadian clock system or alter-
ation of the external environment. Notably, recent epidemiological
data suggest that more than 80% of the population appears to live a
shift work lifestyle (Sulli et al, 2018). This increases the risk for
various chronic diseases such as sleep disorders, cancer, diabetes,
and mood disorders (Zhu & Zee, 2012; Sulli et al, 2018). To restore
normal circadian phase, several approaches are being used. The
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most common is timed light exposure, because light can advance
and delay circadian phase depending on exposure time (Khalsa
et al, 1997). However, as this therapy often requires bright exposure
for up to 2 h daily at specific times, patients show poor compliance
with it, highlighting the need for different approaches. Pharmacolog-
ical phase adjustment of circadian rhythms is considered as an
attractive alternative to timed light exposure (Skelton et al, 2015).
For instance, administration of melatonin in the evening can
advance circadian phase of patients with delayed sleep phase disor-
der (DSPD) (Zhu & Zee, 2012). However, although melatonin given
in the morning can delay circadian rhythms in experimental condi-
tion (Burgess et al, 2010), its clinical efficacy for advanced sleep
phase disorder (ASPD) has not been reported (Sack et al, 2007; Zhu
& Zee, 2012). Furthermore, other clock-modulating drugs including
dopamine partial agonists and GABA receptor modulators have only
shown efficacy in treating DSPD but not ASPD (Ozaki et al, 1989;
Regestein & Monk, 1995; Takaki & Ujike, 2014; Omori et al, 2018;
Takeshima et al, 2018). Given the absence of drugs effectively
delaying circadian phase, PF-670462 (PF-670), a potent and selec-
tive CK1d/e inhibitor currently in preclinical development, is the
most promising candidate compound for treating ASPD as it induces
a large phase delay regardless of dosing timing (Badura et al, 2007;
Kim et al, 2013).
The effect of clock-modulating drugs dramatically changes upon
external light exposure because light also alters the circadian phase.
For instance, the phase shifts induced by PF-670 or melatonin are
attenuated by light exposure (Sprouse et al, 2010; Kim et al, 2013;
Nesbitt, 2018). The effect of clock-modulating drugs is also
proposed to be affected by individual variations in the molecular
cause of circadian disruption and photosensitivity (Holst et al, 2016;
Keijzer et al, 2017). However, the interindividual variability in phar-
macological circadian phase shift caused by differences in individual
genes and environmental lighting conditions has not been systemat-
ically investigated. Thus, whether precision medicine could be
applied as successfully to circadian disruption as it has been to other
areas of medicine such as oncology is currently unclear (Skelton
et al, 2015; Holst et al, 2016; Keijzer et al, 2017). Indeed, current
therapeutics are mainly tailored around the patient’s clinical
features (i.e., phase of sleep–wake cycle) (Zhu & Zee, 2012).
The SCN of diurnal and nocturnal mammals have similar struc-
tures and temporal patterns of the core clock gene expression and
neuronal firing rate (Inouye & Kawamura, 1982; Cohen et al, 2010;
Kumar, 2017; Millius & Ueda, 2018; Mure et al, 2018). Thus, phar-
macomanipulation of the circadian clock has been expected to be
similar in nocturnal and diurnal mammals. However, they display
nearly antiphase rhythms in physiology and behavior (Refinetti,
2006). This suggests that differences may still exist in their
responses to clock-modulating drugs, complicating the translation of
preclinical studies into effective therapies.
We used the response to the selective CK1d/e inhibitor, PF-670,
to dissect any differences in circadian modulation between diurnal
and nocturnal mammals that may be clinically relevant. We found
that nocturnal mice and a diurnal non-human primate (NHP), the
cynomolgus monkey (Macaca facicularis), show a quantitatively dif-
ferent response: PF-670 induces a significantly smaller phase delay
in NHPs than in mice. This interspecies variation was analyzed by
developing a comprehensive systems chronopharmacology model
based on experimental data from the NHPs and humans. The model
simulations for the intracellular interactions of PF-670 with clock
components and follow-up experiments revealed that the weak drug
response of NHPs is mainly due to the strong attenuation of PF-670-
induced phase delay by light exposure, which appears to exist
across many diurnal mammals including humans. This explains the
absence of effective pharmacotherapy for delaying circadian phase
of sleep disorder patients in a daylight cycle (Sack et al, 2007; Zhu
& Zee, 2012). Our work reveals a previously unrecognized biological
variable in translating the efficacy of clock-modulating drugs from
nocturnal mice to diurnal humans: their different photosensitivity.
Besides photosensitivity, we found that the effect of PF-670 on the
circadian phase dramatically decreases as endogenous levels of
PER2 decrease. Together with this finding, our in silico experiments
revealed that depending on the molecular cause of circadian disrup-
tion and the patient’s light exposure, which alters PER2 levels, the
effect of the CK1d/e inhibitor (CK1i) changes. To overcome the
inter- and intraindividual variations, we developed an adaptive
chronotherapeutics that identifies a precise dosing time for CK1i to
restore the normal circadian phase. Our study illustrates how a
systematic approach can both identify sources of variations in drug
response and generate a strategy providing a precise dosing regimen
for circadian disruption.
Results
The effect of PF-670 is more strongly attenuated by light in
diurnal NHPs than in nocturnal mice
PER1/2 phosphorylation by CK1d/e regulates their degradation,
binding to CRY1/2, and nuclear translocation, which are the key
processes of the transcriptional–translational negative feedback loop
of the mammalian circadian clock (Fig 1Ai; Gallego & Virshup,
2007). When CK1d/e is inhibited by PF-670, these processes are
slowed down (Fig 1Ai) and circadian phase is delayed, which is
attenuated by light, the strongest zeitgeber (Fig 1Aii) (Badura et al,
2007; Walton et al, 2009; Meng et al, 2010; Sprouse et al, 2010;
Kim et al, 2013). To analyze the effect of PF-670 on the circadian
phase in diurnal NHPs, and compare it with nocturnal mice, we first
compared the free PF-670 brain concentrations across species (see
Materials and Methods for details). Despite the lower dose level in
NHPs (10 mg/kg (mpk)) than used in our previous study in mice
(32 mpk), the drug exposure in NHPs (AUC = 3.6 lMh) was much
higher than in mice (AUC = 0.5 lMh) (Fig 1B; Kim et al, 2013).
Due to the higher drug exposure in NHPs, we hypothesized that PF-
670 induces a larger phase delay of activity onset in NHPs than in
mice. To investigate this, we compared the phase delays of NHPs
induced by 3-day 10 mpk dosing in a dark–dark cycle (DD) (Fig 1C)
with the phase delays of mice dosed with 32 mpk PF-670 for 3 days
in DD (Kim et al, 2013). Indeed, NHPs showed a significantly larger
phase delay (5.2 h) compared with mice (3.8 h) (P = 0.03; Fig 1E)
(see Materials and Methods for details of phase delay measure-
ment). This larger phase delay in NHPs than in mice might be due
to the different dosing times for NHPs (e.g., CT14) than for mice
(CT11) as the effect of PF-670 changes upon dosing time (Badura
et al, 2007). However, the phase delay of NHP induced by dosing at
CT11 is also likely to be larger than that of mice because the dosing
at CT11 is expected to yield a nearly maximal phase delay (Badura
2 of 16 Molecular Systems Biology 15: e8838 | 2019 ª 2019 The Authors





Figure 1. Light attenuates the effect of PF-670 more strongly in diurnal NHPs than in nocturnal mice.
A PF-670 inhibits the phosphorylation of PER by CK1d/e (i) and delays the circadian phase, which is counterbalanced by light (ii). Thus, daily dosing leads to
continually accumulating phase delay in DD and constant stable phase delay in LD.
B Measured free PF-670 exposure in the brain tissue of mice and NHPs. Drug exposure in NHPs after administration of 10 mpk PF-670 (AUC = 3.6 lMh) is ~7-fold
higher than that in mice given 32 mpk PF-670 (AUC = 0.5 lMh) (n = 2–3; mean  SEM). The mouse data are adopted from (Kim et al, 2013).
C, D Double-plotted actograms of NHPs’ activity for 16 days. NHPs were treated with 10 mpk PF-670 for 3 consecutive days at the same solar time of day: 4 pm for the
DD experiment (C) and 4:30 pm (ZT11) for the LD experiment (D), respectively, which are highlighted as red lines. White and black rectangles indicate the times of
light going on and off (LD 12:12).
E, F Phase delay induced by the 3-day dosing under DD (E) or LD (F). The phase of activity onset in NHPs (10 mpk) is more delayed than that in mice (32 mpk) under DD
(E), but not under LD (F) (n = 3–8; P = 0.03, one-way analysis of variance (ANOVA); n.s., no significant difference). Veh denotes vehicle. The error bars represent
mean  SEM. The mouse data are adopted from (Kim et al, 2013).
G The quantification of (E) and (F) indicates that light has a stronger attenuating effect on the PF-670-induced phase delay in NHPs than in mice (n = 5–8;
mean  SEM; P = 0.036, two-way ANOVA).
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et al, 2007) and the drug exposure is much higher in NHPs than in
mice (Fig 1B) (see Fig EV3 after reading below two sections for
details).
Next, we investigated whether there is also an interspecies dif-
ference in the alteration of PF-670-induced phase delay by light.
Specifically, we compared the phase delays of NHPs induced by 10
mpk dosing for 3 days at zeitgeber time (ZT) 11 in a light–dark cycle
(LD) (Fig 1D) with the previously reported ones of mice dosed with
32 mpk PF-670 under the same conditions (Kim et al, 2013). Despite
the stronger effect of PF-670 in NHPs than in mice under DD
(Fig 1E), NHPs did not show a larger phase delay than mice under
LD (n.s.; Fig 1F). Thus, light attenuates the PF-670-induced phase
delay more strongly in NHPs than in mice (P = 0.036; Fig 1G).
A systems chronopharmacology model is developed to simulate
the effects of PF-670 and light on circadian rhythms of NHPs
NHPs and mice show large differences in the pharmacokinetics of
PF-670 (Fig 1B), and the effect of PF-670 on circadian phase, and
how this is influenced by light (Fig 1E–G). To analyze such multiple
differences systematically, we developed the first systems
chronopharmacology model for NHPs by modifying our previous
model (Kim et al, 2013), which successfully simulates the effects of
PF-670 and light on the intracellular circadian clock of mice. The
modified parts of the model including the newly estimated pharma-
cokinetic parameters and new equations for the light module are
described in the Materials and Methods. See Appendix Equation S1,
Tables EV1 and EV2, and Datasets EV1 and EV2 for the detailed
description for the equations, variables, and parameters of the NHP
model. In the NHP model, inhibition of CK1d/e for PER1/2 phospho-
rylation by PF-670 (Fig 2Ai) and light-induced Per1/2 gene tran-
scription via CREB (Fig 2Aii) were incorporated to simulate the
resulting phase shift of the circadian clock at the molecular level (or-
ange arrow; Fig 2Aiii).
To match the simulated phase shift with the experimentally
observed one in NHPs, firstly in the absence of light, we adjusted
the model parameters describing the pharmacokinetics of PF-670 in
NHPs (Fig 2Ai) (see Fig EV1A–C, Dataset EV1 and Materials and
Methods for details). However, unlike DD dosing, the effect of LD
dosing in NHPs (Fig 1F) was not captured by the model (Fig EV1D
and E), necessitating revision of the light module. In the previous
mouse model, light was assumed to equally promote Per1/2 gene
transcription across the entire circadian phase for simplicity (Kim
et al, 2013). However, the light-induced Per1/2 gene transcription is
known to be suppressed more strongly during the subjective day
than during the subjective night (Albrecht et al, 1997; Shigeyoshi
et al, 1997; Miyake et al, 2000; Kiessling et al, 2014). Therefore, this
gating for light, which reduces photosensitivity of the circadian
clock depending on the circadian time (CT) (Geier et al, 2005), was
incorporated into the light module of the new model (Fig 2Aii).
Furthermore, adaptation for light, which reduces photosensitivity
depending on light duration (Ding et al, 1997; Jagannath et al,
2013; Cao et al, 2015), was also added to further improve the accu-
racy of the light module (Fig 2Aii).
The gating and adaptation, which have not been experimentally
quantified in NHPs, were estimated by fitting the model to the LD
dosing effect that we observed in NHPs (Fig 2B) and human light
phase response curves (PRCs) (Khalsa et al, 1997, 2003) (see
Materials and Methods for details). The shapes of the gating and
adaptation (Fig EV1F and H) were randomly chosen during the esti-
mation process (Fig EV2A–E), However, despite that, we found that
all the identified pairs of gating and adaptation had a similar shape
(Figs 2Aii and EV2F). Specifically, the identified gatings commonly
yielded high photosensitivity during the subjective night, which is
consistent with experimental data from other mammals (Albrecht
et al, 1997; Shigeyoshi et al, 1997; Miyake et al, 2000; Kiessling
et al, 2014). With the identified 10 adaptations, light-induced Per1/
2 gene transcription gradually decreased and reached a 50% reduc-
tion after ~8 h.
The new light module accurately predicts the response of NHPs
to light exposure
As the new light module of the model was estimated mainly based
on the response of humans to light (Fig EV2), we next investigated
whether it could accurately predict the potent light-induced attenua-
tion of the PF-670 effect in NHPs. To solely focus on the effect of
light, we introduced a 3-day 2-h delayed LD on days 8–10, which
mimics the ~2-h phase delay of NHPs induced by the 3-day LD
dosing (Fig 2C). After this 3-day “jet lag”, the delayed phase was
advanced to the original circadian phase for days 11–13. We found
that such light-induced phase shifts that occur during and after jet
lag were accurately predicted by the model with the new light
module (Fig 2D). This indicates that the new light module precisely
captures the light-induced phase advance in NHPs against the PF-
670-induced phase delay in LD dosing.
We next investigated whether the model can predict the
combined effect of PF-670 and light even when the dosing time
changes. We chose dosing at ZT4 as it leads to a much weaker
phase delay in mice than dosing at ZT11 (Badura et al, 2007; Kim
et al, 2013). However, in NHPs, dosing at ZT4 led to a similar phase
delay as dosing at ZT11 (1.5; ZT4 and 1.7 h; ZT11; Fig 2B, E and F).
This unexpected drug effect in NHPs was accurately predicted by
the model with the new light module (Fig 2F), which is mainly due
to the strong attenuation of the drug effect by light in NHPs
(Fig EV3). Taken together, the difference in light response between
mice and NHPs is a critical factor leading to their heterogeneous
response to a clock-modulating drug.
The strong attenuating effect of light is expected in humans
Although the new light module was developed mainly based on the
human response to light (Fig EV2), the model accurately captured
the effect of light in NHPs in both the presence and absence of
dosing (Fig 2). Thus, the strong light-induced attenuation of the PF-
670 effect in NHPs compared with mice (Figs 1G and 3A) is
expected to also exist in humans. To investigate this, we used our
previous finding that the magnitude of the advance zone of the 12-h
light PRC can determine how strongly a 12-h light pulse attenuates
the effect of PF-670 in LD 12:12 (Kim et al, 2013). Indeed, reflecting
the stronger light-induced attenuation in NHPs than in mice
(Figs 1G and 3A), the simulated PRC of NHPs had a larger magni-
tude of the advance zone than the experimentally measured one of
mice (Fig 3B) (Comas et al, 2006). This leads to a higher ratio of
maximum magnitudes between the advance (A) zone and the delay
(D) zone (A/D ratio) of light PRC in NHPs (A/D = 1.25) than in
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mice (A/D = 0.41). This is consistent with experimental studies in
which diurnal animals generally have PRCs with higher A/D ratios
than nocturnal animals (Johnson, 1992). In particular, the human
PRC has a higher A/D ratio than the mouse PRC for both short and
long light pulses (Fig 3C) (Comas et al, 2006; St Hilaire et al, 2012;
Ruger et al, 2013). This supports our proposal that the PF-670-
induced phase delay is also strongly attenuated by external light in
humans, similar to NHPs.
The effect of CK1i depends on individual photosensitivity
Large interindividual variability of photosensitivity up to ~3-fold has
been observed in humans (van der Meijden et al, 2016; Stone et al,
2018; Watson et al, 2018). Given the strong attenuating effect of
light on CK1d/e inhibition in humans (Fig 3C), we would expect a
potentially large variation in CK1i response in individuals with dif-







Figure 2. Systems chronopharmacology model accurately simulates the phase shift of NHPs induced by PF-670 and light.
A Description of the systems chronopharmacology model for NHP. (i) The translocation of PF-670 from plasma to the SCN and its inhibition of PER phosphorylation by
CK1d/e in NHP (Fig EV1A) were accurately modeled to reproduce the PF-670 exposure (Figs 1B and EV1B) and its effect in NHPs (Figs 1E and EV1C). (ii) The
dependence of light-induced Per1/2 gene transcription via CREB on circadian time (gating) and light duration (adaptation) is included in the model (Fig EV1F–H). The
estimated 10 pairs of gating and adaptation allow for the model to successfully reproduce the light-induced phase shift in NHPs and humans (Fig EV2). (iii) The
model simulates the combined effect of PF-670 (i) and light (ii) on PER2 rhythms in the SCN of NHPs.
B The model accurately reproduces the phase delay of NHPs induced by 3-day LD dosing at ZT11. Here, the PF-670-induced phase delay from which the vehicle-
induced phase shift is subtracted was used (n = 8; mean  SEM; Fig 1F). Each orange line is an individual simulation result obtained with each pair of gating and
adaptation in (Aii), and their average is represented by the gray line.
C Double-plotted actogram of NHPs’ activity for 16 days. The light is on at 6 am and off at 6 pm except for days 8 to 10 when the light is on at 8 am and off at 8 pm
(i.e., LD is delayed by 2 h).
D The model successfully predicts the phase shift induced by 2-h jet lag (days 8–10) and its recovery after jet lag (days 11–13) (n = 7; mean  SEM; C).
E NHPs were treated with 10 mpk PF-670 for 3 consecutive days at ZT4 in LD 12:12, which are highlighted as the red line.
F The phase delay induced by 3-day LD dosing at ZT4 (n = 8; mean  SEM; E) is accurately predicted by the model.
ª 2019 The Authors Molecular Systems Biology 15: e8838 | 2019 5 of 16
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the 10 pairs of gating and adaptation (Fig 2Aii), two pairs were
chosen: One has a narrower high photosensitivity zone than the
other (Fig 3E inset) (see Fig EV4A and Dataset EV2 for details).
Thus, the model with the narrow high photosensitivity zone (model
N; Fig 3E) simulates the smaller magnitude of the advance zone of
light PRC than the model with the wide high photosensitivity zone
(model W; Fig 3E). Due to the weaker attenuating effect of light in
model N than in model W (Fig 3E), PF-670 induced a larger phase
delay in model N (Fig EV4B and C). For instance, when a single daily
25 mpk dose is given at ZT8, the PF-670-induced phase delay is
balanced with the light-induced phase advance, and reaches the equi-
librium point after 1 week of dosing (Fig 3F) (Kim et al, 2013). At
this point, with a weaker attenuating effect of light in model N, the
constant stable phase delay induced by PF-670 is larger than in model
W. Furthermore, when a higher dose is used, the effect of CK1i under
LD differs qualitatively depending on individual photosensitivity: The
PF-670-induced phase delay overcomes the light-induced phase
advance, and thus, it accumulates in model N while the phase shift
unstably alternates between delay and advance in model W due to
amplitude suppression (Fig EV4D–G) (Diekman & Bose, 2018). Thus,
the degree of photosensitivity of the individual likely has dramatic
consequences for the effect of clock-modulating drugs.
The effect of CK1i becomes stronger as PER2 levels increase
Due to the larger phase delay induced by PF-670 compared to other
clock-modulating drugs (Subramanian & Subbaraj, 1993; Badura
et al, 2007; Burgess et al, 2010), a daily dosing of PF-670 can induce
a stable phase delay even in the presence of daylight cycle (Fig 3F).
This suggests that daily dosing of CK1i could be a promising first
pharmacological candidate for ASPD. However, as the effect of PF-
670 depends on the dose level and dosing time, those values need to
be carefully selected. This raises the question of what constitutes a
precise dosing regimen to treat ASPD. For instance, to treat ASPD
patients with a 4 h more advanced circadian phase and sleep sched-
ule than healthy people, one candidate regimen would be a single
daily dosing, which is known to induce the ~4-h stable phase delay
in healthy people. Alternatively, dosing time may need to be
advanced by 4 h to reflect the advanced circadian phase of ASPD
patients compared with healthy people, as is done in timed
phototherapy (Bjorvatn & Pallesen, 2009; Zhu & Zee, 2012). Further-
more, dosing regimen could differ depending on the genetics and
environmental lighting conditions of ASPD patients.
To investigate this, we performed a series of in silico experiments




Figure 3. Inter- and intraspecies variability in photosensitivity causes variation in the effect of PF-670.
A The stronger attenuating effect of light in diurnal NHPs than in nocturnal rodents leads to the interspecies variation observed in the response to PF-670.
B The simulated PRCs of diurnal NHPs have a higher ratio of maximal magnitudes between advance and delay zones (A/D = 1.25) than that of the experimentally
measured nocturnal mouse PRC (A/D = 0.41), which is adopted from (Comas et al, 2006). Here, the red line and red range represent the mean  SD of the simulated
12-h light PRCs of the NHP model with different gating and adaptation (Fig 2Aii).
C Similarly, the light PRC of diurnal humans has a higher A/D ratio (St Hilaire et al, 2012; Ruger et al, 2013) than that of nocturnal mice (Comas et al, 2006).
D The effect of PF-670 can be heterogeneous due to interindividual variability in photosensitivity.
E Model N with a narrow high photosensitivity zone (inset) simulates a smaller magnitude of the advance zone of 12-h light PRC than model W with a wide high
photosensitivity zone.
F Thus, model N simulates a larger constant stable phase delay than model W when a single daily 25 mpk dose is given at ZT8 under LD 12:12.
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four dosing regimens that would induce the ~4-h stable phase delay
in the WT model having normal circadian phase, which mimics
healthy people: single daily 26 mpk, 24 mpk, 22 mpk, or 19 mpk
dosing at ZT4, 5, 6, or 7, respectively (blue circles in WT; Fig 4B)
(see Dataset EV2 for details of the WT model). Then, these dosing
regimens are applied to eight different ASPD models, which we
developed by incorporating various mutations including PER2
FASPS (Toh et al, 2001; Vanselow et al, 2006) into the WT model
(see Dataset EV3 and Materials and Methods for details). These
ASPD models simulate a shorter period than the WT model in DD
and thus have a ~4-h more advanced circadian phase in LD
(Fig 4A). Interestingly, the dosing regimens inducing the ~4-h phase
delay in the WT model led to much larger phase delays in all of the
ASPD models, with large variations (blue circles; Fig 4B). On the
other hand, when the dosing times were advanced by 4 h reflecting
the advanced circadian phase of the ASPD models, as is done in
timed phototherapy (Bjorvatn & Pallesen, 2009; Zhu & Zee, 2012),
the model simulated phase delays closer to the desired ~4-h phase
delay (red squares; Fig 4B). Nevertheless, they were still larger. We
found that this is mainly due to the weaker attenuating effect of light
in the ASPD models than in the WT model (Fig EV5A). Importantly,
despite the same clinical feature of the ASPD models (4-h advance)
(Fig 4A), the PF-670-induced phase delay is considerably different
(e.g., Per2t and Cry1t; Fig 4B).
To identify the source of the heterogeneous drug response among
the ASPD models, we estimated the relationship between the effect of
PF-670 (red squares; Fig 4B) and the average level of various core
clock molecules of the ASPD models (Fig EV5B). Interestingly, we
found that the average protein level of PER2 is significantly more
strongly correlated with the effect of PF-670 than that of the other
clock proteins (Fig EV5C). Specifically, as the average PER2 protein
levels (Fig 4A inset) increase in the ASPD models, the effect of PF-670
(red squares; Fig 4B) becomes stronger (Fig 4C). This correlation is
not due to the different free-running period of the ASPD models
(Fig EV5D) and appears to stem from the fact that phosphorylation of
PER2 by CK1d/e is the target of PF-670. Indeed, when we increase
PER2 level in the model by tuning model parameters, the effect of
CK1i becomes stronger regardless of its effect on the free-running
period (Fig EV5E and F). Furthermore, PER2 abundance also explains
the different effect of PF-670 depending on day length: Due to the
higher PER2 abundance at the dosing times in LD 8:16 than in LD 16:8
(Fig EV5G), a larger PF-670-induced phase delay is simulated in LD
8:16 than in LD 16:8 (Fig 4D). To support these in silico predictions
(Fig 4C and D), we estimated the relationship between the effect of
PF-670 and PER2 levels from experimentally measured PRC to PF-670
(Badura et al, 2007) and time series of PER2 levels in the SCN (Amir
et al, 2004). Indeed, we found a strong positive correlation between
them, which is also recapitulated by our model (Fig 4E).
Adaptive chronotherapeutic approach identifies precise
dosing times
We found that the molecular cause of ASPD and the patient’s envi-
ronmental lighting conditions dramatically influence PER2 levels
and thus the effect of CK1i (Fig 4C and D). This dependence of the
drug effect on PER2 level could be used to identify a precise dosing
regimen. That is, due to the accumulation of PER2 during the
daytime (Fig 4A), the drug effect becomes stronger or weaker when
the dosing time of day is delayed or advanced, respectively
(Fig EV4B and C) (Badura et al, 2007; Kim et al, 2013). By using
this feature, we developed an adaptive chronotherapeutic approach:
If the current dosing regimen leads to a weaker or stronger drug
effect than the desired one, the dosing time is delayed or advanced
by 1 h, respectively, until the desired phase delay is achieved
(Figs 5A and EV6A).
To test whether this approach works as expected despite the
large perturbation of the circadian clock (e.g., PER2 abundance and
phase) by genetic variation or environmental lighting conditions,
we applied the adaptive chronotherapeutic approach to all ASPD
models with varying day lengths. Specifically, a single daily 10 mpk
dose was given at ZT3 to the ASPD models in LD 16:8 (day 1;
Fig 5B). Then, depending on the induced phase delay, the initial
dosing time (ZT3) was adjusted according to the chronotherapeutics
(Figs 5A and EV6A). This identified the precise dosing time (colored
number; Fig 5B) inducing the desired phase delay for all ASPD
models regardless of their molecular cause (gray range; Fig 5C).
This chronotherapeutic approach also successfully identified the
precise dosing time when day length changes to LD 8:16 (Fig 5D
and E). Due to the stronger drug effect in LD 8:16 than in LD 16:8
(Fig 4D), the identified precise dosing time was more advanced in
LD 8:16 (Fig 5D) than in LD 16:8 (Fig 5B). Interestingly, even if
ASPD models have the same precise dosing time in LD 16:8 (e.g.,
ZT3 for Per2P and Per2n; Fig 5B), their precise dosing times in LD
8:16 can be different (e.g., ZT3 for Per2P and ZT23 for Per2n;
Fig 5D). This further emphasizes the need for an adaptive
chronotherapeutic approach to reflect the patient’s environmental
lighting condition.
Although solely adjusting the dosing time was successful
(Fig 5B–E), it took longer to achieve the desired phase delay (e.g.,
18 days for Cry2t in LD 8:16; Fig 5D). Furthermore, the identified
precise dosing time could be one at which it is inconvenient to take
a drug (e.g., ZT19 for Cry2t; Fig 5D). This problem can be resolved
if dose level and dosing time are adjusted simultaneously
(Fig EV6B–F).
Discussion
We unexpectedly found that the effect of CK1i on circadian phase
differs between nocturnal mice and diurnal NHPs due to their dif-
ferent levels of photosensitivity: Light attenuates the effect of
CK1i more strongly in NHPs than in mice. Such a strong attenuat-
ing effect of light on a drug-induced phase delay is expected to
exist in humans as their light PRC has a large magnitude of the
advance zone (St Hilaire et al, 2012; Ruger et al, 2013). Thus, the
phase delay induced by melatonin would also be expected to be
strongly attenuated by light. This would explain its weak
effectiveness in treating ASPD and jetlag after westward travel in
a daylight cycle (Sack et al, 2007; Zhu & Zee, 2012; Spiegelhalder
et al, 2017). These results indicate that such interspecies dif-
ference in photosensitivity should be considered when translating
the efficacy of clock-modulating drugs from nocturnal mice to
diurnal humans.
Our systems chronopharmacology model based on experimental
data from NHPs and humans predicts that a regimen reflecting a
patient’s individual circadian phase can achieve a more precise
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Figure 4. CK1i induces a larger phase delay as PER2 levels increase depending on the molecular cause of ASPD and external lighting conditions.
A The simulated period of ASPD models is shorter than that of the WT model in DD. Thus, they have a ~4 h more advanced phase than the WT model in LD 12:12
(inset). PER2 protein concentrations in each mutant are normalized to the maximum PER2 concentration of the WT model (dashed gray line; inset).
B The phase delays induced by a single daily dosing of PF-670 were simulated. The dosing regimens inducing ~4-h phase delays in the WT model led to much larger
phase delays in all ASPD models with large inter- and intravariations (blue circles). When the dosing times are advanced by 4 h reflecting the advanced phase of the
ASPD models, the phase delays become closer to but still larger than the ~4-h phase delays (red squares).
C As the average PER2 level is higher in the ASPD models (A), PF-670 induces a larger phase delay. Here, the phase shift is the average of the phase delays represented
as the red squares in (B). The line represents the least-square fitting line. r and P denote the Pearson’s correlation coefficient and P-value of Pearson’s correlation test,
respectively. a denotes the slope of the least-square fitting line.
D The ASPD models simulate the larger PF-670-induced phase delay in LD 8:16 than in LD 16:8 due to the higher PER2 level in LD 8:16 than in LD 16:8 when dosing
occurs (Fig EV5G).
E Consistently, higher experimentally measured PER2 levels in the SCN (n = 4; mean  SEM; Amir et al, 2004) at the dosing time leads to a larger PF-670-induced
phase delay (n = 3–20; mean  SEM; Badura et al, 2007), which was also captured by the NHP model when 20 mpk dosing was used.
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therapeutic effect than a non-circadian-based regimen. This may
explain why the current circadian-based treatment can alleviate
sleep disorders (Zhu & Zee, 2012; Sletten et al, 2018). However, our
model predicts that even if the circadian phase of patients is similar,
their response to CK1i can be considerably different depending on
the molecular cause and the environmental lighting condition
(Fig 4A–D). We found that such variability in the CK1i effect is
mainly due to altered PER2 abundances (Figs 4C–E and EV5B–F).
While the interspecies difference in PER2 abundance has not been
investigated, it may contribute to the interspecies variability in the
CK1i effect (Figs 1E–G and 3A). Furthermore, the interspecies dif-
ference in the phase of PER2 rhythms (Vosko et al, 2009; Zhang
et al, 2014; Millius & Ueda, 2018; Mure et al, 2018), which leads to
the interspecies difference in PER2 abundance when dosing occurs,
could also be the source of the interspecies variability in the CK1i
effect. It would be interesting to investigate such a relationship
between the effect of CK1i and PER2 abundance, and extend this to
other clock-modulating drugs and their target molecules (e.g.,
KL001 targeting CRY; Hirota et al, 2012). Furthermore, as PER2




Figure 5. An adaptive chronotherapeutic approach identifies the precise dosing regimen.
A By tracking the patients’ heterogeneous drug response caused by different genetics and environments, adaptive chronotherapeutics adjusts the dosing time: If the
current dosing regimen leads to a weaker or stronger drug effect than the desired one, the dosing time is delayed or advanced by 1 h, respectively (see Fig EV6A for
details).
B, C By adjusting the initial dosing time (ZT3) according to the adaptive chronotherapeutics, the precise dosing time can be obtained for each ASPD model (colored
number; B), with which a single daily 10 mpk dosing leads to the desired ~4-h phase delay in LD 16:8 (gray range; C).
D, E When day length decreases to 8 h (LD 8:16), the precise dosing times are considerably advanced.
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2016), altered PER2 levels depending on genetics and environmental
lighting conditions could vary the level of p53 as well. This may also
explain the large inter- and intrapatient variability in the
chronotherapy of antitumor drugs (Altinok et al, 2009; Levi et al,
2010).
Our work indicates that patient-specific molecular and lifestyle
information should be integrated to achieve a desired therapeutic
effect of clock-modulating drugs (Fig 4B–D). However, because
obtaining such information can be challenging, we developed an
adaptive chronotherapeutics, which identifies the precise dosing
time to achieve normal circadian phase by tracking the patient’s
drug response (Figs 5A and EV6A and B). This adaptive
chronotherapeutics requires a precise quantification of the drug-
induced circadian phase shift in daily life. Recently, to overcome
the insufficient accuracy of actigraphy and labor-intensive
measurement of dim light melatonin onset (Duffy & Dijk, 2002;
Ancoli-Israel et al, 2003), various methods have been developed,
which are based on the metabolite timetable (Kasukawa et al,
2012), one-time phase estimation (Wittenbrink et al, 2018), or
sleep-tracking using mobile phone (Walch et al, 2016). With
these advances, the adaptive chronotherapeutics could play a
critical role in incorporating biomarker data and providing real-
time patient-tailored chronotherapy via smart devices (i.e., digital
medicine) (Elenko et al, 2015).
Materials and Methods
Reagents and Tools table
Reagent/Resource Reference or Source Identifier or catalog number
Experimental models
Mauritian Cynomolgus Monkey (Macaca
fascicularis)
Charles River BRF, Inc.
PF-670462 Pfizer Medicinal Chemistry, Groton,
Connecticut USA
Plasma protein binding Biopharma Drug Disp 23: 327–338
Brain tissue binding J Pharm Sci 105: 965–971
Chemicals, enzymes, and other reagents
Sulfobutyl ether b-cyclodextrin Sigma-Aldrich CAT 1065550
Control monkey plasma Bioreclamation www.bioivt.com
Acetonitrile Fisher Chemical CAT A998
Ammonium formate Sigma-Aldrich CAT 78314
Acetic acid Fisher Chemical A38-S
Ammonium acetate Sigma-Aldrich A7262
Isopropyl alcohol Fisher Chemical A461-1
Software
Analyst Software v 1.4.2 AB Sciex, Inc. https://sciex.com/products/
software/analyst-software
Actical Software Philips Respironics, Bend, Oregon
ClockLab v6.0.52 Actimetrics, Inc. Wilmette, IL
Wolfram mathematica Wolfram Research, Inc. https://wolfram.com
GraphPad Quickcalcs software GraphPad Software, Inc. http://www.gra
phpad.com/quickcalcs/index.cfm
Other
Actical activity monitor Philips Respironics, Bend, Oregon Model IPX7
ActiReader Philips Respironics, Bend, Oregon Model 1063543
Actical animal armored primate collar Philips Respironics, Bend, Oregon CAT 198-0032-00M
Digital light meter Amprobe, Inc. Model LM631A
Purina Lab Diet W.F. Fisher and Son CAT 5K91
Vacutainer spray-coated K2EDTA Becton Dickinson Company CAT 367835
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Reagents and Tools table (continued)
Reagent/Resource Reference or Source Identifier or catalog number
AB Sciex API4000 tandem quadrupole mass
spectrometer
AB Sciex, Inc. https://sciex.com/products/ma
ss-spectrometers/triple-quad-systems/api-
4000-system
Shimadzu LC20AD pumps Shimadzu Scientific Instruments https://
www.ssi.shimadzu.com/products/liquid-
chromatography/lc-20ad.html
CTC PAL autosampler Leap Technologies https://www.leaptec.c
om/collections/instruments/products/pal3
Synergi Max RP UPLC analytical liquid





All procedures involving animals were conducted with the approval
of the Pfizer IACUC and were compliant with the Guide for the Care
and Use of Laboratory Animals and the regulations and standards of
the Animal Welfare Act (9CFR2, 9CFR3). Eight 5- to 6-year-old male
Mauritian Cynomolgus macaques (Charles River BRF, Inc.) SPF for
CHV-1, SRV 1, SRV 2, and SRV 5, STLV1, and SIV were used for
behavioral studies. Six animals were pair-housed and two singly
housed. All monkeys were chair-trained and fitted with collar-
mounted Actical activity monitors (Philips Respironics, Bend,
Oregon, USA). The Actical Software (Respironics ActiReader) was
set to record activity counts in 5-min bins. ClockLab 6.0.52 (Acti-
metrics Wilmette, IL) was used to generate actograms and to deter-
mine activity onset and free-running periods. Animals were
acclimated and housed in a room under 12:45/11:15 LD with a 45-
min ramping period to full light on/off as simulated dawn/dusk
(i.e., at 5:15 am lights started ramping up to full lights on at 6:00
am; at 5:15 pm lights started ramping down to completely off at
6:00 pm). The direct light intensity in the room was 1,300 lux at 1
meter from the floor in the middle of the room, which is measured
using a digital light meter (Model LM631A, Amprobe, Everett, WA).
For constant dim light conditions, the light intensity was ~14 lux
measured at the cage face. Animals were placed under dim light
conditions for 2 weeks prior to study onset and were under dim
light conditions for 4 months during the study. Animals were fed
Purina LabDiet 5K91 (W.F. Fisher and Son) twice daily, and reverse
osmosis purified municipal water was provided ad libitum. Daily
environmental enrichment was provided in the form of fruit treats
and manipulada. Animals were chair-restrained for drug administra-
tion and data download from the Actical monitors.
The sample size for behavioral studies was determined to detect
the desired magnitude of difference (≥ 20 min), and the variance of
the estimates was based on previous data where available and
setting a = 0.05 and 1-b = 0.9. One animal was identified as an
outlier in a 2-h jet lag experiment (Fig 2C) by Grubbs’ test
(a = 0.01) and was thus excluded from the analysis.
Study design
A cross-over design was used for each treatment limb, and animals
were randomized into 2 groups of 4 prior to each dosing limb.
PF-670462 was dissolved in 20% w/v sulfobutyl ether b-cyclodex-
trin, and filter sterilized. Formulations were prepared 1–2 h prior
to administration and given subcutaneously for 3 consecutive
days at solar time: 4:00 pm in DD and 4:30 pm in LD. Prior to DD
dosing (Fig 1C), 4 NHPs were placed in DD for 2 weeks to esti-
mate their free-running period. Their different intrinsic periods
(23.8, 24, 24.1, and 24.3 h) caused them to be initially dosed at
different CTs (CT4, 6, 8, and 14 h) since the CT when the initial
dosing occurs was calculated by considering the activity onset at
the pre-dosing day as CT0. Prior to LD dosing (Figs 1D and 2E),
NHPs were placed in LD for at least 10 days for a stable base line
(i.e., entrainment). This allowed for them to be initially dosed at
the same ZT11. For the light-induced phase shift experiment
(Fig 2C), following 7 days of stable activity, the time for lights




PF-670462 was synthesized and characterized by Medicinal Chem-
istry at Pfizer Worldwide Research and Development (WRD).
Animal studies were performed in accordance with the Guide for the
Care and Use of Laboratory Animals (Clark et al, 1996) using proto-
cols reviewed and approved by the WRD IACUC.
1 A single dose (10 mpk, SC) of PF-670462 was prepared in 20%
sulfobutyl ether b-cyclodextrin in water (10 mg/ml).
2 The dose was administered (1 ml/kg) to male cynomolgus
macaque monkeys by subcutaneous route (N = 2).
3 Serial blood samples were collected from the femoral vein at 0,
0.25, 0.5, 0.75, 1, 2, 4, 6, and 24 h post-dose into Vacutainer
(Becton Dickinson Company, Franklin Lakes, NJ) blood
collection tubes pretreated with EDTA and placed immediately
on ice.
4 The whole blood samples were centrifuged for 10 min at 2,300 × g
and plasma transferred to clean tubes for storage at20°C.
Monkey pharmacokinetic samples were prepared and analyzed
using a non-validated bioanalytical assay. For standard curve
preparation, the plasma was purchased from Bioreclamation Inc.,
Hicksville, NY.
5 The standard curves were prepared in control cynomolgus
monkey plasma via serial dilution at a concentration range of
0.5–1,000 ng/ml.
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6 An aliquot of plasma (50 ll) was precipitated with acetonitrile
(MeCN) (300 ll) containing an internal standard.
7 Samples were vortex-mixed (1 min) and centrifuged (180 rcf for
10 min) to afford supernatant (250 ll), which was transferred to
a 96-well plate.
8 Supernatants were evaporated under N2 at 37°C and reconsti-
tuted in 25% MeCN in H2O (100 ll).
Samples were analyzed by an LC-MS/MS comprising an AB Sciex
API 4000 tandem quadrupole mass spectrometer (AB Sciex Inc.,
Ontario, Canada) with a TurboIonSpray probe (AB Sciex Inc., Ontar-
io, Canada), tertiary Shimadzu LC20AD pumps (Shimadzu Scientific
Instruments, Columbia, MD), and a CTC PAL autosampler (Leap
Technologies, Carrboro, NC). Instrument settings and potentials
were adjusted to provide optimal data. All raw data were processed
using Analyst Software version 1.4.2 (AB Sciex Inc., Ontario,
Canada).
PF-670462 and its internal standard within sample aliquots (5 ll)
were eluted at 0.5 ml/min on a Synergi Max RP analytical column
(4 l, 80 A˚, 2 × 30 mm; Phenomenex, Torrance, CA) using 10 mM
ammonium formate in 0.1% HCO2H (solvent A) and MeCN (solvent
B) via the following gradient: 0 to 0.75 min, 5% solvent B; 0.75 to
1.25 min, 5 to 90% B; 1.25 to 2.00 min, hold at 90% B; and 2.00 to
2.5 return to 5% B and hold until 3.00 min. Mass spectral data were
collected in positive electrospray ionization mode using multiple-
reaction monitoring (MRM) following the m/z 338.2?256.2 frag-
mentation for PF-670462.
Plasma protein binding
The plasma-free fraction of PF-670462 was determined in monkey
plasma by equilibrium dialysis using a previously reported method
(Kalvass & Maurer, 2002).
1 Aliquots (200 ll, n = 6) of freshly harvested monkey plasma
containing PF-670462 (1 lM) were loaded into a 96-well equilib-
rium dialysis apparatus (HTDialysis, Gales Ferry, CT) containing
preconditioned Spectra-Por2 membranes (Spectrum Laboratories
Inc., Rancho Dominguez, CA; molecular weight cutoff 12,000–
14,000).
2 Plasma was dialyzed against an equal volume of phosphate-
buffered saline for 6 h at 37°C.
3 After incubation, 150 ll of plasma sample and 150 ll of buffer
sample were removed from the apparatus and matrix-matched
for bioanalysis by addition of an equal volume of opposing
matrix to yield identical sample composition between buffer and
non-buffer samples.
Protein binding samples were analyzed by HPLC/MS/MS using a
non-validated bioanalytical assay.
4 An aliquot of matrix-adjusted sample (50 ll) was precipitated
with acetonitrile (MeCN) (200 ll) containing an internal stan-
dard.
5 Samples were vortex-mixed (2 min) and centrifuged (1,811 rcf
for 7 min) to afford supernatant (150 ll), which was transferred
to a 96-well plate.
Samples were analyzed by an LC-MS/MS comprising an AB Sciex
API 4000 tandem quadrupole mass spectrometer (AB Sciex Inc.,
Ontario, Canada) with a TurboIonSpray probe (AB Sciex Inc.,
Ontario, Canada), tertiary Shimadzu LC20AD pumps (Shimadzu
Scientific Instruments, Columbia, MD), and a CTC PAL autosampler
(Leap Technologies, Carrboro, NC). Instrument settings and poten-
tials were adjusted to provide optimal data. All raw data were
processed using Analyst Software version 1.4.1 (AB Sciex Inc., Ontar-
io, Canada).
PF-670462 and its internal standard within sample aliquots
(10 ll) were eluted at 0.4 ml/min on a Luna C18 analytical column
(5 l, 80 A˚, 2.1 × 30 mm; Phenomenex, Torrance, CA) using 50%
20 mM ammonium acetate in 0.1% isopropyl alcohol, and 50%
acetonitrile (solvent A) and MeCN (solvent B) via the following
gradient: 0–0.5 min, 10% solvent B; 0.5–1.5 min, 10–90% B; 1.5–
2.20 min, hold at 90% B; and 2.21 return to 10% B and hold until
3.00 min. Mass spectral data were collected in positive electrospray
ionization mode using MRM following the m/z 338.2?256.2 frag-
mentation for PF-670462.
The plasma-free fraction was calculated from the ratio of concen-
trations determined from the plasma and buffer samples.
Estimation of free brain concentration
Free PF-670462 brain concentration was estimated from plasma by
first correcting for the fraction of unbound PF-670462 in plasma
(fu = 0.15) and subsequently correcting for the free brain and free
plasma concentration ratio (Cbu/Cpu) of 1, an approach commensu-
rate with unrestricted equilibrium between the central and plasma
compartments as predicted by physiologically based PK modeling
(Trapa et al, 2016).
Modeling studies
Mathematical model description
We adopted our previous systems chronopharmacology model (274
variables and 86 parameters), which successfully investigated the
effect of PF-670462 in mice (Kim et al, 2013). This model was devel-
oped by extending the Kim–Forger model (Kim & Forger, 2012), a
detailed mathematical model of the intracellular mammalian circa-
dian clock, which describes the reactions among core clock mole-
cules (e.g., binding, phosphorylation, subcellular translocation,
transcription, and translation) using ordinary differential equations
based on mass action kinetics (181 variables and 75 parameters).
To develop the systems chronopharmacology model for NHP
(Fig 2A), the original mouse model (Kim et al, 2013) was modified
by newly estimating the pharmacokinetic (PK) parameters (Fig 2Ai)
and incorporating the gating and adaptation into the light module of
the model (Fig 2Aii).
Modification of the PK parameters
The six parameters describing the PK properties of PF-670462 (e.g.,
transfer rate between plasma and brain tissue) were modified due to
the difference in free PF-670462 exposure in brain tissues (Fig 1B)
and its effect in DD (Fig 1D) between NHPs and mice. Specifically,
the parameters were fitted to the disposition profiles of PF-670 and
its DD dosing effect in NHPs (see Fig EV1A–C and Dataset EV1 for
details).
Incorporation of gating and adaptation for light into the model
To incorporate the gating into the model, we used the function g,
which determines the photosensitivity of the circadian clock at each
CT (Fig EV1F). To connect the photo-insensitive and photosensitive
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zones of g, a piecewise polynomial interpolation was used (see Code
EV1). To incorporate the adaptation into the model, we used the Hill
function, which expresses light duration-dependent reduction in
photosensitivity (Fig EV1H).
The values of six parameters determining the functions of gating
and adaptation (Dataset EV2) were estimated with the simulated
annealing (SA) method (Gonzalez et al, 2007) and post-filtering in
two steps. In the first round, we found 991 parameter sets with
which the model accurately simulates the phase delay of NHPs
induced by the 3-day LD dosing and the magnitude of human PRC
to a 6.7-h light pulse (Fig EV2A) using SA method with the cost
function:
where f1ðxÞ ¼ 10
3 If max jmj; jMjð Þ  6
0 If max jmj; jMjð Þ\6

:
m and M are the min and max of the simulated PRC to a 6.7-h light
pulse, respectively. ~m = 3.26 and ~M = 2.63 h are the min and
max of the human PRC to a 6.7-h light pulse, respectively (Khalsa
et al, 2003). xj and ~xj are the simulated phase delay and experimen-
tally measured phase delay (Fig 1D) on day j of 3-day LD dosing,
respectively.
In the second round, using post-filtering, we filtered in the
final 10 parameter sets (Dataset EV2) with which the model accu-
rately simulates the type 1 PRC to a 12-h light pulse and the
human PRC to a 6.7-h light pulse and to 3-cycle 5-h light pulses
(Fig EV2).
To estimate the input CT for g even when the circadian phase is
perturbed, we constructed the function p which determines the CT
from an internal pace marker: the phase angle of the limit cycle of
two clock variables, revng and revnp in the model (Fig EV1G). We
first interpolated the phase angles of the limit cycle of revng and
revnp to the CTs. Then, we composed the interpolation function
with the function, tan1 (revng(t), revnp(t)), which estimates the
phase angle of the limit cycle from the concentrations of revng and
revnp at t. As gp is the composite of the interpolation functions,
which do not have explicit form, including gp into the model
increases the computational cost of the simulation. Thus, the
approximated gp using Fourier series was used, which accurately
determines the phase-dependent photosensitivity even when the
circadian phase is altered by PF-670462 or light.
Development of the ASPD models
To develop the ASPD models (Dataset EV3), we investigated the
modification of which parameter allows for advancing the phase by
~4 h from the WT model (Fig 4A), reflecting the advanced circadian
phase of ASPD patients (Jones et al, 1999). In this process, to reflect
the advanced circadian phase, the phase of gating function g is also
advanced by 4 h.
Model assumptions
1 The model of the intracellular mammalian circadian clock, Kim–
Forger model, which was developed to accurately simulate the
mouse SCN (Kim & Forger, 2012), was used for the new NHP
model as clock gene expression profiles in the SCN of cynomol-
gus monkeys have not been measured. Nevertheless, due to the
new light module, the NHP model simulates more advanced
clock gene expression compared with the original mouse model
under LD, which is consistent with the advanced clock gene
expression seen in the SCN of baboons compared with that of
mice under LD (Mure et al, 2018).
2 The pharmacodynamic parameters, describing the intracellular
action of PF-670462 (e.g., binding of PF670 with CK1d/e), of the
original systems chronopharmacology model (Kim et al, 2013),
were kept as they are expected to be similar between NHPs and
mice.
3 The reduced photosensitivity due to adaptation for light during
daytime is assumed to be completely recovered after nighttime if
it is long enough (≥ 8 h).
4 To simulate the phase shift of activity onsets with the model, we
used the phase shift of the simulated BMAL1 gene expression
profile as the phase of BMAL1 gene expression profiles and activ-
ity onset is highly correlated (Kiessling et al, 2010). However, as
the phases of all clock gene expression profiles are tightly inter-
locked in the model, the result changes little even if the phase of
other clock gene expression profiles is used.
Simulation
All the simulations and parameter searches were performed
using MATHEMATICA 11.0 (Wolfram Research, Champaign, IL)
with a computer cluster composed of seven machines where
each machine is equipped with two Intel Xeon SP-6148 CPUs
(2.4 GHz, 20C), 192GB RAM, and the operating system CentOS
7.4 64bit.
Statistical analysis
For this study, one-way ANOVA, two-way ANOVA, and Pearson’s
correlation test were used to determine statistical significance.
Outliers were detected by Grubbs’ test. They are each detailed along
with the relevant parameters in the main text, figures, and figure
legends. A P-value of < 0.05 was considered statistically significant.
One-way ANOVA, two-way ANOVA, and Pearson’s correlation test
were performed using MATHEMATICA 11.0. Grubbs’ test was
performed using GraphPad Quickcalcs software (GraphPad Software
Inc, La Jolla, CA, USA, available at http://www.graphpad.com/quic
kcalcs/index.cfm).
Data availability
The MATHEMATICA codes used in this study are available in Code
EV1 and the following database: https://github.com/daewookkim/
Non-human-primate-circadian-clock-model-including-CK1-inhibitor.
Expanded View for this article is available online.
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